Brief report: Acamprosate in fragile X syndrome

Craig A. Erickson, Jennifer E. Mullett, Christopher J. McDougle

Research output: Contribution to journalArticle

56 Scopus citations


Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism.

Original languageEnglish (US)
Pages (from-to)1412-1416
Number of pages5
JournalJournal of Autism and Developmental Disorders
Issue number11
StatePublished - Nov 1 2010


  • Acamprosate
  • Fragile X syndrome
  • Irritability
  • Language
  • MGluR5

ASJC Scopus subject areas

  • Developmental and Educational Psychology

Fingerprint Dive into the research topics of 'Brief report: Acamprosate in fragile X syndrome'. Together they form a unique fingerprint.

Cite this